Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

No longer available × INDUSTRY × osimertinib × Clear all

Status

Active not recruiting 30 Completed 27 Recruiting 22 Not yet recruiting 8 Terminated 6 Unknown 5 Withdrawn 1 No longer available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

EGFR T790M Mutation Positive NSCLC 1

Interventions

dabrafenib 4 trametinib 3 nilotinib 3 midostaurin 3 elotuzumab 3 Nivolumab 3 talimogene laherparepvec 2 regorafenib 2 Suspensions 2 Prednisone 2 Powders 2 Panobinostat 2 Melphalan 2 Lenalidomide 2 Ipilimumab 2 Everolimus 2 Dexamethasone 2 Bortezomib 2 zanubrutinib 1 zanidatamab 1 venetoclax 1 veliparib 1 tucatinib 1 tazemetostat 1 taletrectinib 1 surufatinib 1 sugemalimab 1 selitrectinib 1 ruxolitinib 1 rovalpituzumab tesirine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02451852 2016-07-14

AZD9291 US Expanded Access Program

AstraZeneca

No longer available

EGFR T790M Mutation Positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡